Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Breast Cancer
Phase Not Applicable
Enrollment 130
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

Triple negative breast cancer (TNBC) is the most aggressive of breast cancers and it is usually treated with chemotherapy even before surgery. In many cases, the chemotherapy completely "melts" the tumor and these patients do well. When the tumor is not eliminated by the chemotherapy, the patient receive more chemotherapy after surgery to decrease the chances of it coming back. Yet many of these patients don't need that extra chemotherapy and will do well in any case. One of the most exciting recent developments in cancer is the use of "liquid biopsies". It turns out that the tumor's DNA, RNA and proteins can be detected in small vesicles found in the patient's blood. Thanks to advances in Artificial Intelligence, there is now informatics tools to integrate many types of molecular information. Our industrial partner, MIMs, will apply novel informatics tools to generate a test using all the molecular information obtained from blood vesicles and tissue that will be able to find out early if tumor has spread outside of the breast, and how much tumor is left after surgery. The goal is hope to develop a multi-dimensional test for TNBC patients that can be used to decide how much treatment they need and if treatment given after surgery is working.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: Liquid Biopsy — Blood collection and access to residual tumor.

Primary Outcomes

  • Develop signatures of good and poor outcome as well of tumor response to chemotherapy in TNBCs by integrating multidimensional profiling of both tumor and liquid biopsies making use of Artificial Intelligence (AI) tools (3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2019-12-05
Completion: 2027-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 130 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Jewish General Hospital
Collaborators: Exactis Innovation
Principal Investigators:
  • Mark Basik, Dr (PRINCIPAL_INVESTIGATOR) - Study Principal Investigator
Contact Information
Study Contact:
Adriana Aguilar, PhD
514-340-8222
nanaaguilar@gmail.com
Josiane Lafleur, MSc
514-340-8222
josiane.lafleur.jgh@gmail.com
Kalan S. Lynn, MSc
519-646-6100
kalan.lynn@lhsc.on.ca
St. Joseph's Health Care London
Interventions
  • Other: Liquid Biopsy — Blood collection and access to residual tumor.
Study Locations (3 sites)
St. Joseph's Health Care London, London, Ontario N6A 4V2 Canada
The Ottawa Hospital Cancer Center, Ottawa, Ontario K1H 8L6 Canada
Jewish General Hospital, Montreal, Quebec H3T 1E1 Canada
Eligibility Criteria
Inclusion Criteria: * Triple negative (ER negative, PR negative and Her2 negative as defined by local standards). ER \<10% is acceptable. * Patients who have completed a minimum of 8 weeks of neoadjuvant chemotherapy. * A cohort of TNBC patients who are awaiting surgery that have clinical or radiological evidence of residual tumor prior to surgery. This evaluation will be made at the discretion of the treating physician. OR A second cohort of TNBC patients will be recruited after surgery, in which pathological evaluation has demonstrated the presence of residual tumor post-surgery. * Patients who can come to the clinic for standard of care follow-up within 6 weeks post-surgery and in the next 6 months after surgery. * Patients who are willing to provide serial blood samples. * Participants must be willing and able to comply with scheduled visits, treatment schedule, laboratory testing, and other requirements of the study. Exclusion Criteria: * Clinical or radiological evidence of metastatic disease. * Patient with a recurrence of breast cancer. * Patients who have not had neoadjuvant chemotherapy or less than 8 weeks of neoadjuvant chemotherapy. * Patient who received radiotherapy treatment prior to surgery. * Patients who are not capable of signing or understanding the informed consent form. * Known infection with HIV or hepatitis.
Conditions Triple Negative Breast Cancer
Phase PHASE2
Enrollment 46
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

This is an prospective, open label, multicenter study to evaluate the efficacy and safety of neoadjuvant serplulimab plus weekly paclitaxel and carboplatin in patients with triple-negative breast cancer.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Serplulimab — 1.5mg/kg qw, start from C1D15
  • Drug: Paclitaxel — 80mg/m\^2 qw
  • Drug: Carboplatin — AUC=1.5, D1, 8, 15, every 28 days

Primary Outcomes

  • Proportion of patients with pCR (1-2 weeks after surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-03-01
Completion: 2031-09
Eligibility
Age: 18 Years – 70 Years
Sex: FEMALE
Volunteers: false
Enrollment: 46 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: RenJi Hospital
Principal Investigators:
  • Wenjin Yin, M.D. (PRINCIPAL_INVESTIGATOR) - Renji Hospital,School of Medicine, Shanghai Jiaotong University
Contact Information
Study Contact:
Wenjin Yin, M.D.
86(21)68385569
yinwenjin@renji.com
Wenjin Yin, M.D.
86(21)58852345
yinwenjin@renji.com
Renji Hospital, School of Medicine, Shanghai Jiaotong University
Interventions
  • Drug: Serplulimab — 1.5mg/kg qw, start from C1D15
  • Drug: Paclitaxel — 80mg/m\^2 qw
  • Drug: Carboplatin — AUC=1.5, D1, 8, 15, every 28 days
Study Locations (1 sites)
Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127 China
Eligibility Criteria
Inclusion Criteria: * Female, Aged ≥18 and ≤70 years * Histologically confirmed triple negative breast cancer (ER\<10%, PR\<10%, and HER2 negative) * Subjects with at least one evaluable lesion * ECOG 0-1 * Adequate organ function Exclusion Criteria: * Metastatic disease (Stage IV) * Female patients who are pregnancy, lactation or women who are of childbearing potential tested positive in baseline pregnancy test;Female patients of childbearing age that are reluctant to take effective contraceptive measures throughout the trial period
Conditions Cancer, Breast Cancer
Phase NA
Enrollment 21
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

In this pilot study, the investigators will assess the changes in myokine production based on several different exercise regimens.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Behavioral: Conditioning Resistance Training — Participants in this group will perform a conditioning regimen from the EXERT-BCHC protocol, specifically described as "double training".
  • Behavioral: Strength Resistance Training — Participants in this group will perform a strength regimen from the EXERT-BCHC protocol, specifically described as "8x8".
  • Behavioral: Hypertrophy Resistance Training — Participants in this group will perform a hypertrophy regimen from the EXERT-BCHC protocol, specifically described as the "control arm".

Primary Outcomes

  • Change in Myokine Production After First Exercise Session (Immediately before and immediately after the first exercise session.)
  • Change in Myokine Production After Final Exercise Session of Each Week (Immediately before and immediately after the final exercise session of weeks 1, 2, 3, and 4.)
  • Change in Myokine Production After Final Exercise Session of the Month (End of Study) (Immediately before and immediately after the final exercise session of week 4 (end of the 4-week exercise regimen).)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-07-06
Completion: 2028-07
Eligibility
Age: 20 Years – 89 Years
Sex: FEMALE
Volunteers: false
Enrollment: 21 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Principal Investigators:
  • Colin Champ, MD (PRINCIPAL_INVESTIGATOR) - AHN Radiation Oncology
Contact Information
Study Contact:
Clinical Trials Contact
412-330-6151
ctgov@ahn.org
Clinical Trials Contact
412-330-6151
clinicaltrials@ahn.org
AHN Allegheny General Hospital
Clinical Trials Contact
4123306151
ctgov@ahn.org
Allegheny General Hospital
Interventions
  • Behavioral: Conditioning Resistance Training — Participants in this group will perform a conditioning regimen from the EXERT-BCHC protocol, specifically described as "double training".
  • Behavioral: Strength Resistance Training — Participants in this group will perform a strength regimen from the EXERT-BCHC protocol, specifically described as "8x8".
  • Behavioral: Hypertrophy Resistance Training — Participants in this group will perform a hypertrophy regimen from the EXERT-BCHC protocol, specifically described as the "control arm".
Study Locations (2 sites)
AHN Allegheny General Hospital, Pittsburgh, Pennsylvania 15212 United States
Allegheny General Hospital, Pittsburgh, Pennsylvania 15212 United States
Eligibility Criteria
Inclusion Criteria: 1. Age 20-89 years 2. Women prescribed exercise as a SOC 3. Women with a biopsy proven diagnosis of ductal carcinoma in situ (DCIS) or invasive carcinoma of the breast 4. Women must have undergone treatment for breast cancer, including one or more of the following: surgery, radiation therapy, chemotherapy, immunotherapy, or hormonal therapy. Women undergoing active chemotherapy are not allowed on study. Immunotherapy or targeted agent usage is allowed. 5. Women with \> 3 months of resistance training experience under expert guidance at the Allegheny Health Network Exercise Oncology Center Exclusion Criteria: 1. Any current treatment with cytotoxic chemotherapy for breast cancer 2. Inability to safely engage in group sessions of resistance training as deemed by study PI 3. Severe arthritic, joint, cardiovascular, or musculoskeletal condition deemed by PI to be unsafe to engage in resistance training 4. Pregnant women 5. Males
Conditions Diabetes Mellitus, Type 2, Obesity, Cort...
Phase Not Applicable
Enrollment 3200
Locations 5 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

The present observational cross-sectional study is aimed to assess: the hidden hypercortisolism (HidHyCo) prevalence in a sample of Type 2 diabetes (T2D) patients and the clinical characteristics more frequently associated with the HidHyCo presence and the HidHyCo prevalence in an adequate sample of obese patients without T2D and the clinical characteristics more frequently associated with the HidHyCo presence.

Design

Study type: Observational Observational model: Cohort Time perspective: Cross Sectional

Interventions / Regimen

  • Diagnostic Test: 1mg DST — measurement of cortisol levels after 1 mg of dexamethasone (DST) at 11 pm

Primary Outcomes

  • Hidden Hypercortisolism prevalence in a sample of T2D patients (24 months)
  • Hidden Hypercortisolism prevalence in a sample of Obese patients (24 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-05-06
Completion: 2025-12-06
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 3200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Istituto Auxologico Italiano
Collaborators: University of Siena, Niguarda Hospital, Campus Bio-Medico University, Azienda Ospedaliero Universitaria, Santa Maria della Misericordia di Udine, Italy
Contact Information
Study Contact:
Valentina Morelli, PhD
02619112547
v.morelli@auxologico.it
Valentina Morelli
02619112547
v.morelli@auxologico.it
Istituto Auxologico Italiano
Iacopo Chiodini, Prof
+39026444.3376
iacopo.chiodini@ospedaleniguarda.it
Niguarda Hospital
Interventions
  • Diagnostic Test: 1mg DST — measurement of cortisol levels after 1 mg of dexamethasone (DST) at 11 pm
Study Locations (5 sites)
Istituto Auxologico Italiano, Milan, 20135 Italy
Niguarda Hospital, Milan, 20162 Italy
Campus Bio-Medico University, Roma, 00128 Italy
University of Siena, Siena, 53100 Italy
Azienda Ospedaliero Universitaria, Santa Maria della Misericordia di Udine, Udine, 33100 Italy
Eligibility Criteria
Inclusion Criteria: patients with T2D and Obesity Exclusion Criteria: * pregnancy/breast feeding, * sleep apnea, * prepuberal onset of hypertension, hormonal hypersecreting adrenal mass, * symptoms of hypercortisolism; * already known secondary hypertension; * conditions associated with increased hypothalamic-pituitary-adrenal (HPA) axis activity, -severe autoimmune/rheumatologic and hematologic diseases, alcoholism, kidney disease (glomerular filtration rate \<60) * drugs influencing the HPA axis activity. For inclusion in Group 2 the presence of T2D will be an exclusion criteria
Conditions T2DM (Type 2 Diabetes Mellitus)
Phase NA
Enrollment 88
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to evaluate whether an evidence-based anti-inflammatory dietary intervention can reduce inflammation and improve glycemic control in patients with type 2 diabetes mellitus (T2DM). T2DM is a chronic metabolic disease characterized by elevated blood glucose levels and is closely associated with chronic low-grade inflammation. The main questions it aims to answer are: Does an anti-inflammatory dietary intervention reduce levels of hs-CRP, a key marker of chronic inflammation, in patients with T2DM? Does the intervention improve dietary inflammatory index (DII) scores and glycemic outcomes, including fasting blood glucose and 2-hour postprandial blood glucose? Researchers will compare an anti-inflammatory diet intervention group to a standard diabetes dietary control group to determine whether the anti-inflammatory dietary pattern provides additional benefits beyond routine dietary management. Participants will: Be randomly assigned to either the anti-inflammatory diet group or the standard diabetes diet group Receive dietary guidance based on structured anti-inflammatory food recommendations or routine diabetes dietary advice Complete dietary assessments, including 24-hour dietary recalls to calculate dietary inflammatory index (DII) Provide blood samples to measure hs-CRP, fasting blood glucose, and 2-hour postprandial blood glucose at baseline and after 4 weeks Complete questionnaires on dietary adherence and quality of life Participate in a 4-week intervention period with follow-up assessments

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Anti-inflammatory Dietary Intervention — Participants in this group will receive a 4-week evidence-based anti-inflammatory dietary intervention in addition to routine diabetes care.
  • Behavioral: Standard Diabetes Dietary Advice — Participants will receive routine dietary guidance for diabetes management according to standard clinical dietary recommendations for 4 weeks.

Primary Outcomes

  • high-sensitivity C-reactive protein (hs-CRP) (Week 4)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-06-03
Completion: 2026-11
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 88 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Anhui Medical University
Contact Information
Study Contact:
Huimin Guo
+8615399593640
2445011323@stu.ahmu.edu.cn
Huimin Guo
+8615399593640
2445011323@stu.ahmu.edu.cn
The First Affiliated Hospital of Anhui Medical University
Interventions
  • Behavioral: Anti-inflammatory Dietary Intervention — Participants in this group will receive a 4-week evidence-based anti-inflammatory dietary intervention in addition to routine diabetes care.
  • Behavioral: Standard Diabetes Dietary Advice — Participants will receive routine dietary guidance for diabetes management according to standard clinical dietary recommendations for 4 weeks.
Study Locations (1 sites)
The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230000 China
Eligibility Criteria
Inclusion Criteria: 1. Patients who meet the diagnostic criteria for type 2 diabetes mellitus (T2DM) according to the Guidelines for the Prevention and Treatment of Type 2 Diabetes Mellitus in China (2020 Edition); 2. Aged 18 years or older; 3. Able and willing to complete all study questionnaires; 4. Willing to provide blood samples for laboratory testing; 5. Possessing adequate communication and comprehension abilities, with no impairment of consciousness, and able to respond to investigators' questions; 6. Willing to participate in regular follow-up visits and assessments according to the study protocol and able to provide written informed consent. Exclusion Criteria: 1. Patients with a history of diseases affecting blood glucose metabolism, such as hyperthyroidism or Cushing's syndrome; 2. Pregnant or breastfeeding women; 3. Patients with severe hepatic dysfunction, renal dysfunction, heart failure, or malignant tumors; 4. Patients with acute or chronic infectious diseases accompanied by obvious signs of infection, including clinically diagnosed intestinal infections, respiratory tract infections, periodontitis, and other infectious conditions; 5. A history of recent use of medications that may affect inflammatory or metabolic status, such as nonsteroidal anti-inflammatory drugs (NSAIDs, e.g., aspirin) or glucocorticoids; 6. Patients who have undergone gastrointestinal surgery or have diseases that may affect the effectiveness of dietary intervention, such as malabsorption syndrome.
Conditions Type 2 Diabetes (T2DM)
Phase PHASE4
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

Medications that enhance the incretin effect (GLP-1 receptor agonists, tirzepatide (GIP/GLP-1 receptor agonist) and DPP-4 inhibitors) are used in treatment of patients with type 2 diabetes. GLP-1 agonists and tirzepatide not only effectively lower blood glucose levels but also promote weight loss-primarily by stimulating the satiety center in the central nervous system - and reduce cardiovascular risk. Evidence suggests that oral pancreatin supplementation also enhances the incretin effect by increasing GIP and GLP-1 concentrations, and consequently insulin levels, which translates into a reduction in postprandial glycemia in patients with cystic fibrosis or chronic pancreatitis. In our study we aim to evaluate the impact of pancreatin on the incretin effect and glycemic control in patients with type 2 diabetes without exocrine pancreatic insufficiency.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: Pancreatin — Pancreatin 25 000 U with each of the 3 main meals daily for 3 months
  • Drug: Placebo — Placebo capsule with each of the 3 main meals daily for 3 months

Primary Outcomes

  • Glycemic control (3 months)
  • Time in range (3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2026-08-01
Completion: 2027-12-31
Eligibility
Age: 35 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Silesian Centre for Heart Diseases
Collaborators: Medical University of Silesia
Principal Investigators:
  • Marta Wróbel, PhD (PRINCIPAL_INVESTIGATOR) - Department of Internal Medicine, Diabetology and Cardiometabolic Disorders
Contact Information
Study Contact:
Marta Wróbel, PhD
48606873060
mwrobel@sum.edu.pl
Paulina Piekarz-Ząbek, MD
‭+48 604 223 652‬
k_bielawa@poczta.fm
Marta Wróbel, PhD
+48606873060
mwrobel@sum.edu.pl
Department of Internal Medicine, Diabetology and Cardiometabolic Disorders, Faculty of Medical Sciences Zabrze
Interventions
  • Drug: Pancreatin — Pancreatin 25 000 U with each of the 3 main meals daily for 3 months
  • Drug: Placebo — Placebo capsule with each of the 3 main meals daily for 3 months
Study Locations (1 sites)
Department of Internal Medicine, Diabetology and Cardiometabolic Disorders, Faculty of Medical Sciences Zabrze, Zabrze, Silesian Voivodeship 41-800 Poland
Eligibility Criteria
Inclusion Criteria: * Type 2 diabetes diagnosed for at least 12 months * Patients treated with oral antihyperglycemic agents and/or insulin as monotherapy or combination therapy * Age between 35 and 75 years * HbA1c: 6.5% - 9.0% Exclusion Criteria: * Type 1 diabetes * Use of incretin-based drugs (GLP-1 receptor agonists, dual GIP and GLP-1 receptor agonists, DPP-4 inhibitors) currently or within the last 3 months * History of pancreatic surgery * History of chronic pancreatitis * History of acute pancreatitis
Conditions Type 1 Diabetes Mellitus
Phase PHASE2
Enrollment 60
Locations 6 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

This is a 2-arm, multi-center, open label study to learn if ATG works the same or better than teplizumab in delaying or preventing Stage 3 Type 1 diabetes. Participants will be administered either 2 infusions of ATG or 14 infusions of teplizumab and will then be followed for at least 12-48 months after administration, depending on timepoint enrolled into the study. If the primary endpoint demonstrates a positive signal and as decided by TrialNet, there is potential for a study extention. This would extend follow-up visits for a possible study duration of about 9 years among the earliest enrollees of the initial study.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Drug: Antithymocyte Globulin (ATG) — Thymoglobulin
  • Drug: Teplizumab — Intravenous infusions of teplizumab given for 14 consecutive days. For participants ages 8-34 each infusion will take a minimum of 30 minutes. For participants ages 4-7 each infusion will take a minimum of 2 hours. Each infusion will also be followed by an observation period of at least 30 minutes.

Primary Outcomes

  • Change in DPTRS at six months (6 months after completion of study drug administration)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-07-29
Completion: 2030-05-30
Eligibility
Age: 4 Years – 34 Years
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Principal Investigators:
  • Michael Haller, MD (STUDY_DIRECTOR) - TrialNet Chairman
  • David Baidal, MD (STUDY_CHAIR) - TrialNet
  • Vandana Raman, MD, MBBS (STUDY_CHAIR) - TrialNet
Contact Information
Study Contact:
Melissa Parker
813-396-9378
melissa.parker@epi.usf.edu
Leah Galvez Valencia
303-724-4992
leah.galvezvalencia@ucdenver.edu
Barbara Davis Center
Lexie Chesshir
303-724-8615
lexie.chesshir@CUANSCHUTZ.EDU
Barbara Davis Center
Interventions
  • Drug: Antithymocyte Globulin (ATG) — Thymoglobulin
  • Drug: Teplizumab — Intravenous infusions of teplizumab given for 14 consecutive days. For participants ages 8-34 each infusion will take a minimum of 30 minutes. For participants ages 4-7 each infusion will take a minimum of 2 hours. Each infusion will also be followed by an observation period of at least 30 minutes.
Study Locations (6 sites)
Barbara Davis Center, Aurora, Colorado 80045 United States
Yale University, New Haven, Connecticut 06511 United States
University of Florida, Gainesville, Florida 32610 United States
Columbia University, New York, New York 10032 United States
University of Pittsburgh, Pittsburgh, Pennsylvania 15224 United States
Benaroya Research Institute, Seattle, Washington 98101 United States
Eligibility Criteria
Inclusion Criteria: * Willing to provide informed consent or have a parent or legal guardians provide informed consent when the participant is \<18 years of age. * Aged ≥4 to \<35 years * A history of at least two or more diabetes-related biochemical autoantibodies (mIAA, GADA, ICA, IA-2A, ZnT8A) present on the same sample. In the absence of other antibodies, ICA and GADA positivity alone will not suffice for eligibility in this trial. * Participants must meet ADA stage 2 T1D glycemic criteria\* by TrialNet testing within 100 days of the baseline visit. \*The ADA definition of stage 2 T1D is characterized by glucose intolerance or dysglycemia in the presence of two or more islet autoantibodies, impaired fasting glucose (≥ 100mg/dL), impaired glucose tolerance (2-hour post 75g glucose load ≥ 140mg/dL), high glucose levels at intermediate time points on OGTT (30, 60, 90 min timepoints of ≥ 200 mg/dL), and/or HbA1c between 5.7% and 6.4% or ≥ 10% increase in HbA1c within a two year window, with the most recent HbA1c value obtained within 100 days of the baseline visit. * Participants, regardless of serostatus, must meet all of the following: * Be EBV and CMV PCR negative prior to randomization * Be EBV and CMV PCR negative within 2 weeks prior to the baseline visit * Have no signs or symptoms of a CMV or EBV-compatible illness lasting longer than 7 days within 30 days prior to the baseline visit. * Be at least 8 weeks from last live immunization at the time of the baseline visit. * Be willing to forgo vaccines (other than non-live influenza and COVID-19) during the 3 months after study drug treatment period and forgo live vaccines for 12 months after study drug treatment period. * Must meet TrialNet eligibility minimum immunization recommendations found in Appendix A of the manual of operations (MOO). * With the exception of stage 2 T1D, participants must be healthy, as defined by absence of any other untreated diagnoses that the investigator deems to be a potential confounder. * If a female participant with reproductive potential, willing to avoid pregnancy (abstinence or adequate contraceptive method) through the completion of the study infusions and up to 3 months after study drug administration and undergo pregnancy testing prior to each study visit. * Must be residing or have accommodations within 1 hour of the infusion site during study drug infusions and must be within 1 hour of a medical care facility for 1 day after completion of infusions. * Participants must live in a location with rapid access to emergency medical services. Exclusion Criteria: * Immunodeficiency or clinically significant chronic lymphopenia: (Leukopenia (\<3,000 leukocytes/μL), neutropenia (\<1,500 neutrophils/μL), lymphopenia (\<1000 lymphocytes/μL), thrombocytopenia (\<150,000 platelets/μL). * Hemoglobin less than 13 g/dL for adult men and less than 11.5g/dL for adult females and less than 11 g/dL for participants under age 18. * Active signs or symptoms of acute or chronic infection at the time of the baseline visit including SARS-Cov-2. * Uncontrolled autoimmune thyroid disease and/or celiac disease (participants must be well controlled for the previous 6 months). * Evidence of prior or current tuberculosis infection through any one or more of the following: 1. A history of latent or active TB 2. Signs and/or symptoms of TB 3. Recent close contact with a person with known or suspected active TB unless appropriate prophylaxis for TB was given 4. A history of a chest X-ray consistent with active TB or old, inactive TB, or interferon gamma release assay IGRA (QuantiFERON) test 5. A history of a positive purified protein derivative (PPD) skin test result (\>10 mm induration), or positive/repeatedly indeterminate on an interferon-gamma release assay (IGRA; e.g., QuantiFERON-TB test). * Currently pregnant or lactating or anticipate getting pregnant within the study period. * Require use of other immunosuppressive agents including chronic use of oral or intravenous injectable steroids. * Evidence of current or past HIV or Hepatitis B or current Hepatitis C infection. * Any complicating medical issues or abnormal clinical laboratory results that may interfere with study conduct, or cause increased risk to include pre-existing cardiac disease, COPD, sickle cell disease, Down syndrome, adrenal insufficiency, neurological disease, or blood count abnormalities. * A history of malignancies other than of skin. * Evidence of liver dysfunction with AST or ALT ≥ 2 times the upper limit of the reference range. * Evidence of renal dysfunction with creatinine ≥ 1.5 times the upper limit of the reference range. * Increased bilirubin ≥ 2 times (total) or ≥ 1.5 times (direct) the normal limit (Participants with documentation of Gilbert's Disease permitted). * Vaccination with a live vaccine within the last 8 weeks or killed/inactivated vaccine within the last 2 weeks of the baseline visit. * Current or ongoing use of non-insulin pharmaceuticals that affect glycemic control within 14 days of screening. * Prior treatment with Teplizumab or ATG (either in a previous clinical trial or clinically). * Has previously participated in a clinical trial for diabetes prevention and received active study agent within 6 months of treatment. * Known allergy to rabbits or rabbit derived products. * Prior adverse reactions to heparin. * Any condition that in the investigator's opinion may adversely affect study participation. * Any screening/baseline laboratory result not otherwise stated out of normal reference range and/or medical history that may increase the risk of the participant's participation in this trial. * Previously diagnosed with Stage 3 TID according to ADA criteria.
Conditions Obesity or Overweight
Phase PHASE3
Enrollment 2500
Locations 212 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: AZD6234 — IMP injected subcutaneously, once a week. Unit dose strength as per CSP.
  • Drug: Placebo — Placebo matching IMP dose injected subcutaneously, once a week.

Primary Outcomes

  • Percent change in body weight from baseline at 68 weeks of treatment (68 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2026-08-19
Completion: 2029-05-21
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 2500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: AstraZeneca
Contact Information
Study Contact:
AstraZeneca Clinical Study Information Center
1-877-240-9479
information.center@astrazeneca.com
Interventions
  • Drug: AZD6234 — IMP injected subcutaneously, once a week. Unit dose strength as per CSP.
  • Drug: Placebo — Placebo matching IMP dose injected subcutaneously, once a week.
Study Locations (212 sites)
Research Site, Dothan, Alabama 36305 United States
Research Site, Huntsville, Alabama 35801 United States
Research Site, Mesa, Arizona 85206 United States
Research Site, Escondido, California 92025 United States
Research Site, Clearwater, Florida 33765 United States
Research Site, Jacksonville, Florida 32205 United States
Research Site, Stockbridge, Georgia 30281 United States
Research Site, Champaign, Illinois 61822 United States
Research Site, Chicago, Illinois 60640 United States
Research Site, Ames, Iowa 50010 United States
Eligibility Criteria
Inclusion Criteria: * Males \& females (inclusive of all gender identities) age ≥18 years * BMI ≥30 kg/m2 OR BMI ≥27 kg/m2 with at least one of the following weight related comorbidities (treated or untreated): hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, heart failure, chronic kidney disease, metabolic dysfunction-associated steatotic liver disease, osteoarthritis of the knee, or stress urinary incontinence * Stable body weight (≤5% body weight change) for at least 3 months prior to Randomisation * History of at least one self-reported unsuccessful attempt to lose body weight in their lifetime Exclusion Criteria: * Obesity primarily caused by other endocrine disorders * History of Type 1 or Type 2 Diabetes Mellitus, HbA1c ≥6.5% (48 mmol/mol), and/or treatment with glucose-lowering agent(s) within 3 months prior to Screening * Significant hepatobiliary disease and/or any of the following results at Screening: * ALT ≥ 3.0 × ULN * AST ≥ 3.0 × ULN * TBL \> 1.5 × ULN (except for cases of known Gilbert's Syndrome) * Has received treatment with a GLP-1 receptor agonist or GLP-1 containing medication for any indication within 3 months before Randomisation.
Conditions Type 2 Diabetes, Cortisol Excess
Phase PHASE2
Enrollment 1500
Locations 61 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

CAPTAIN-T2D will take place in two parts. Part 1 (Screening) will evaluate patients with type 2 diabetes and elevated cortisol risk factors for trial eligibility and the presence of elevated cortisol. Participants deemed eligible from Part 1 will be randomized to either clofutriben or placebo in the double-blind (participant and investigator), dose-ranging, interventional Part 2 (Treatment).

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: clofutriben — HSD-1 inhibitor
  • Drug: Placebo — Placebo

Primary Outcomes

  • Percentage of patients with both morning serum cortisol >1.8 mg/dL and morning plasma dexamethasone >=140 ng/dL (single composite endpoint) after a single dexamethasone 1 mg dose taken the prior night. (8-10 hours after the dexamethasone 1 mg dose.)
  • Glycated hemoglobin A1c (%) change from baseline to Week 24 by treatment. (24 weeks.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-11-29
Completion: 2028-06-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sparrow Pharmaceuticals
Contact Information
Study Contact:
Kamila Manager
480-470-4000
kojeda@azclinicaltrials.com
Arizona Clinical Trials - Pecos
Leanne Manager
480-470-4000
lbuchenholz@azclinicaltrials.com
Arizona Clinical Trials - Broadway
Lizeth Manager
323-588-1990
lsuncin@velocityclinical.com
Ark Clinical Research - Fountain Valley
Interventions
  • Drug: clofutriben — HSD-1 inhibitor
  • Drug: Placebo — Placebo
Study Locations (61 sites)
Arizona Clinical Trials - Pecos, Chandler, Arizona 85225 United States
Arizona Clinical Trials - Broadway, Tucson, Arizona 85711 United States
Ark Clinical Research - Fountain Valley, Fountain Valley, California 92708 United States
Velocity Clinical Research, Huntington Park, Huntington Park, California 90255 United States
Velocity Clinical Research - Gardena, La Mesa, California 91942 United States
Ark Clinical Research - Long Beach, Long Beach, California 90815 United States
Los Angeles Institute for Metabolic Research, Los Angeles, California 90015 United States
Velocity Clinical Research, Los Angeles, Los Angeles, California 90057 United States
Amicis Research Center- Nordhoff, Northridge, California 98433 United States
Alliance Clinical San Diego, San Diego, California 92120 United States
Eligibility Criteria
Inclusion Criteria: * From Screening 1 * Age at least 18 years. * HbA1c ≥7.5% documented within 3 months prior to Screening 1. (The historical HbA1c value must have been obtained after at least 2 months on the current \[as of Screening 1\] regimen). * Treatment with stable and adequate doses of ≥2 injectable or oral ADMs. (An ADM will be deemed stable if the dose has been the same for at least 3 months prior to Screening 1 and without change between Screening 1 and Day 1) (An ADM dose will be deemed adequate if it is at or above the maximal labelled dose, or a sub-maximal, but not starting, dose if limited by tolerability (confer with MM if less than half-maximal dose). * Adequate total daily insulin is defined as at least 0.3 units/kg/day. Insulin dose will be deemed stable with adjustments of up to 20% total daily dose during the 3 months prior to Screening 1 or between Screening 1 and Day 1. * Use of insulin pumps or insulin brand changes (e.g., due to insurance change or shortage) are to be discussed with the MM. * At least one of the following * ≥3 stable and adequate ADMs; * diabetes complication (retinopathy, nephropathy, neuropathy, atherosclerotic heart disease); * hypertension requiring ≥2 adequately dosed AHMs; * adequately dosed basal or basal plus prandial insulin in addition to at least 1 other ADM; and * adequately dosed incretin agonist (a single or combination agent counts as one ADM) in addition to at least 1 other ADM; * evidence or history of osteoporosis or non-traumatic fracture (e.g., vertebral body compression); * or established diagnosis of a neoplastic (non-malignant) source of hypercortisolism and have failed, are ineligible for, or declined surgery. At DST • Post-DST cortisol level \>1.8 µg/dL and serum dexamethasone ≥140 ng/dL. Patients with an established diagnosis of neoplastic hypercortisolism do not require a DST. At Screening 2 * HbA1c ≥7.5% at Screening 2. At Day 1 * No change in, or initiation of, medications for hypertension within 1 month prior to Day 1. Exclusion Criteria: * New-onset diabetes (onset \<1 year in the past). * Unwillingness to maintain with current glucose-lowering regimen during the trial. * Unwillingness to adjust, add, replace, or discontinue current or other glucose-lowering medications during the trial as directed by the investigator. * Unwillingness to comply with CGM or other trial procedures. * Investigator considers the patient will otherwise be unwilling or unable to complete the trial. * Night-shift worker or otherwise habitually awake from 23:00 to 07:00 h. * Evidence for significant hypoglycemia while on their current diabetic treatment regimen(This includes episodes of symptomatic Level 3 hypoglycemia requiring external assistance for recovery, or CGM-documented prolonged \[\>15 min\] or repeated episodes of either Level 2 hypoglycemia leading to \>1%, or Level 1 hypoglycemia leading to \>4%, in "time below range" within 3 months prior to Screening 1 or between Screening 1 and Day 1). * Any of the following in medical history: * Type 1 diabetes mellitus (T1D), latent autoimmune diabetes in adults (LADA), or familial forms of maturity-onset diabetes of the young (MODY); * A hemoglobinopathy or other condition which may interfere with measurement of HbA1c (e.g., sickle cell disease HbSS or other variants HbEE thalassemia, hemolytic anemia, recent blood transfusion); * Hypersensitivity or severe reaction to dexamethasone; * Pheochromocytoma, or suspicion thereof; * Anorexia, or other eating disorder; * Glucocorticoid resistance; * Multiple sclerosis; * Significant hepatic impairment (e.g., Child-Pugh Class B or C); * Idiopathic thrombocytopenic purpura; * Untreated or inadequately controlled moderate-to-severe sleep apnea (apnea-hypopnea index ≥15). (Patients whose condition has been well controlled with Continuous Positive Airway Pressure (CPAP) use for at least 3 months prior to Screening 1 are not excluded. Patients with a STOP-BANG score 5-8 should be referred for a sleep study outside the trial and may rescreen if found not to have moderate-to-severe sleep apnea); * Current alcohol consumption \>14 units/week or \>4 units in a single day for males, or \>7 units/week or \>3 units in a single day for females. (Patients with a CAGE score 2-4 should be evaluated further outside the trial and may be rescreened if found not to have an alcohol \[or other substance\] use disorder); * Untreated or inadequately controlled major depressive disorder, generalized anxiety disorder, bipolar disorder, post-traumatic stress disorder, or schizophrenia.(Patients whose condition has been well controlled with stable medical therapy, or has been asymptomatic, for at least 3 months prior to Screening 1 are not excluded); or * Any other medical condition (including malignancy) that is likely to interfere with trial assessments or the patient's ability to complete the trial. * Any of the following in medication history: * Any of the excluded medications listed in Section 6.9; * Any investigational drug within 4 weeks or within less than five times the drug's half-life, whichever is longer, prior to Screening 1 or between Screening 1 and Day 1; * Woman of childbearing potential (WOCBP) not willing to adhere to highly effective contraception or strict abstinence for the duration of the trial and for 90 days post completion/discontinuation; and * Pregnancy (including a positive urine test) or current breast feeding. From Screening 2 • Prior probability of undiagnosed endogenous Cushing syndrome based on either of: * wo morning serum cortisol values after dexamethasone suppression \>5.0 mcg/dL together with plasma dexamethasone \>140 ng/mL; or * a morning serum cortisol value after dexamethasone suppression \>1.8 mcg/dL, together with plasma dexamethasone \>140 ng/mL and any one of the following that is not attributable to an etiology other than endogenous Cushing's syndrome: * supraclavicular/dorsocervical fat accumulation; * irounding of the face (especially compared with prior photos); * skin changes (violaceous striae, skin thinning, or excessive bruising); * proximal muscle weakness on exam; or * history of deep vein thrombosis/pulmonary embolism. * Plans for, or medically unable to forego, treatment for endogenous Cushing syndrome or ACS within the next 8 months. (For clarity, patients with EnCS or ACS, not having such treatment plans, and medically able to forego treatment for 8 months may enroll if otherwise eligible). * Severe, poorly controlled hypertension (mean systolic BP \>160 mmHg or mean diastolic BP \>100 mmHg) at Screening 2 or between Screening 2 and Day 1, including by at-home monitoring. (Such patients will be eligible to rescreen for Part 2 when they restore BP \<160/100 mmHg for 1 month on a new stable medication regimen). * Positive urine screen for recreational drugs (except tetrahydrocannabinol (THC)). * Glomerular filtration rate (GFR) (determined using Chronic Kidney Disease Epidemiology Collaboration \[CKD-EPI\]) \<45 mL/min/1.73 m². * Poorly controlled hyperthyroidism/hypothyroidism (confirmed by TSH or Free thyroxine \[fT4\]). * Liver enzymes \>3 × upper limit of normal (ULN) (alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or bilirubin \>1.5 × ULN.(excepting benign conditions such as Gilbert's) * Known hypersensitivity to clofutriben or to any of the product
Conditions Obesity Difficult Airway Airway Manageme...
Phase NA
Enrollment 300
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

The OBESIAL (Obesity Structured Intervention in Algeria) study aims to evaluate the clinical, metabolic, and organisational impact of a structured multidisciplinary obesity care pathway implemented under real-world conditions.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Semaglutide (Wegovy) weekly injection — Semaglutide (Wegovy®) will be administered as a subcutaneous injection once weekly, with gradual dose escalation according to the recommended dosing schedule for the molecule, up to a target maintenance dose of 2.4 mg once weekly, for 12 months. Semaglutide will be initiated as an adjunct to the structured OBESIAL obesity care pathway in eligible participants randomized to G1a, following a second written informed consent specifically for the pharmacological intervention.
  • Behavioral: Behavioral Treatment — Structured care group (G1): Only participants in G1 will undergo the structured care pathway over 18 months. * Individualised nutritional follow-up adapted to the sociocultural context, consisting of eight sessions, including nutritional education sessions lasting 30 minutes and evaluation sessions lasting 15 minutes. * An individually tailored physical activity programme based on baseline functional capacity and associated comorbidities. Participants will be encouraged to attend supervised or structured physical activity sessions three times per week, with adjustments according to tolerance and clinical status. * Psychological support provided according to individual needs, focusing on motivation, emotional eating, barriers to adherence, and behavioural change strategies. The frequency of psychological follow-up will be adapted to patient requirements, reflecting the pragmatic nature of the intervention.
  • Other: Weight loss — The content of care is not standardized or imposed by the OBESIAL protocol and may vary according to local clinical practices, healthcare professionals' habits, available resources, treatment availability, and therapeutic options accessible within the participating healthcare structures. Usual care may include lifestyle and dietary management, physical activity advice or interventions, behavioral support, pharmacological treatment for obesity when clinically indicated and available, including GLP-1 receptor agonist therapy, and other therapeutic options for obesity according to usual clinical practice and individual patient characteristics. Bariatric surgery may also be considered or performed when clinically indicated according to the usual care pathway of the healthcare structure.

Primary Outcomes

  • Percentage of Participants Achieving ≥5% Weight Loss at Month 18 (18 months follow-up)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-01-22
Completion: 2028-01-23
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Health Sciences, Algeria
Principal Investigators:
  • Mounira Chanegriha, Professor (PRINCIPAL_INVESTIGATOR) - University of health sciences, Faculty of Medicine, Algiers, Algeria
Contact Information
Study Contact:
Mounira Professor Chanegriha. Head of Medicine department, Professor
+21321905656
m.chanegriha@univ-alger.dz
Interventions
  • Drug: Semaglutide (Wegovy) weekly injection — Semaglutide (Wegovy®) will be administered as a subcutaneous injection once weekly, with gradual dose escalation according to the recommended dosing schedule for the molecule, up to a target maintenance dose of 2.4 mg once weekly, for 12 months. Semaglutide will be initiated as an adjunct to the structured OBESIAL obesity care pathway in eligible participants randomized to G1a, following a second written informed consent specifically for the pharmacological intervention.
  • Behavioral: Behavioral Treatment — Structured care group (G1): Only participants in G1 will undergo the structured care pathway over 18 months. * Individualised nutritional follow-up adapted to the sociocultural context, consisting of eight sessions, including nutritional education sessions lasting 30 minutes and evaluation sessions lasting 15 minutes. * An individually tailored physical activity programme based on baseline functional capacity and associated comorbidities. Participants will be encouraged to attend supervised or structured physical activity sessions three times per week, with adjustments according to tolerance and clinical status. * Psychological support provided according to individual needs, focusing on motivation, emotional eating, barriers to adherence, and behavioural change strategies. The frequency of psychological follow-up will be adapted to patient requirements, reflecting the pragmatic nature of the intervention.
  • Other: Weight loss — The content of care is not standardized or imposed by the OBESIAL protocol and may vary according to local clinical practices, healthcare professionals' habits, available resources, treatment availability, and therapeutic options accessible within the participating healthcare structures. Usual care may include lifestyle and dietary management, physical activity advice or interventions, behavioral support, pharmacological treatment for obesity when clinically indicated and available, including GLP-1 receptor agonist therapy, and other therapeutic options for obesity according to usual clinical practice and individual patient characteristics. Bariatric surgery may also be considered or performed when clinically indicated according to the usual care pathway of the healthcare structure.
Study Locations (1 sites)
Department of Medicine, , Mother and Child Hospital of the Army (MCHA), Algiers University Hospital, Algiers, Algeria., Algiers, 16000 Algeria
Eligibility Criteria
Inclusion Criteria: * Adults aged 18-65 years * BMI ≥30 kg/m² * Written informed consent obtained prior to enrolment Exclusion Criteria: * Refusal to participate or inability to adhere to follow-up procedures * Pregnancy at enrolment * Severe or unstable comorbidities compromising safety or participation, including: * Recent acute cardiovascular event (\<60 days) * Active malignancy * Severe unstable organic disease * Previous bariatric surgery * Obesity pharmacotherapy within the previous 90 days * Known contraindication to planned therapeutic options * Severe unstable psychiatric disorders * Genetic obesity or obesity secondary to uncontrolled endocrine disease Exclusion Criteria During Follow-up * Pregnancy occurring during follow-up * Initiation of chronic treatment associated with weight gain
Conditions Type 1 Diabetes (T1D), Type 2 Diabetes, ...
Phase NA
Enrollment 240
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this randomized controlled trial is to compare the efficacy and safety of the iLet Bionic Pancreas (BP) System in adults with insulin-treated diabetes (type 1 diabetes or type 2 diabetes) compared to standard of care when ordered by primary care providers. The main question it aims to answer is: Can the iLet BP by deployed in primary care settings to adults with insulin-treated diabetes (type 1 diabetes or type 2 diabetes)? Researchers will compare 13-weeks of iLet BP use to routine care to see if iLet BP use has a greater reduction in HbA1c compared to13-weeks of routine care. Participants will: Use the iLet BP for 13-weeks or continue their routine care Be trained to use the study devices or continue their routine care Complete a virtual screening visit, mid-period follow up calls and a final visit Complete baseline CGM collection Complete surveys and fingerstick a1c blood tests Routine care participants will have the option to complete an observational extension phase where they will wear the iLet BP for 13-weeks

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Bionic Pancreas — The intervention group will use the iLet Bionic Pancreas (BP) for 13-weeks. They will be trained on the iLet BP system and its components by a Certified iLet Trainer. They will also be trained on how to use the study continuous glucose monitor (CGM) system, blood glucose meter, and ketone meter. Participants will have four mid-period follow up phone calls to review medications, ongoing eligibility, and solicit any occurrences of adverse events and device issues. At the end of 13-weeks, they will complete final visit tasks and will be transitioned back to their pre-study insulin delivery method with guidance provided by a study investigator.
  • Other: Routine Care — Participants will continue with their current diabetes treatment. Participants will be trained on the use of the study blood glucose meter. They will have four mid-period follow up phone calls to review medications, ongoing eligibility, and solicit any occurrences of adverse events. At the end of 13-weeks, they will complete final visit tasks and will be asked if they would like to participate in the observational extension phase where they will use the iLet Bionic Pancreas for 13 weeks.

Primary Outcomes

  • HbA1c between the BP and RC groups (RCT Week 13)
  • Percentage of Time With CGM Glucose <54 mg/dl (RCT Weeks 1-13 and OEP Weeks 13-26)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-01-16
Completion: 2029-04-01
Eligibility
Age: 18 Years – 89 Years
Sex: ALL
Volunteers: false
Enrollment: 240 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Colorado, Denver
Collaborators: Massachusetts General Hospital, Beta Bionics, Inc., Ann & Robert H Lurie Children's Hospital of Chicago
Principal Investigators:
  • Sean Oser, MD, MPH, CDCES (PRINCIPAL_INVESTIGATOR) - University of Colorado, Denver
Contact Information
Study Contact:
Jessica Parascando, MPH
303-724-9525
primarycarediabeteslab@cuanschutz.edu
Elizabeth Westfeldt, BSN, RN
303-724-9525
elizabeth.westfeldt@cuanschutz.edu
Jessica Parascando, MPH
303-724-9525
jessica.parascando@cuanschutz.edu
University of Colorado Anschutz Medical Campus
Interventions
  • Device: Bionic Pancreas — The intervention group will use the iLet Bionic Pancreas (BP) for 13-weeks. They will be trained on the iLet BP system and its components by a Certified iLet Trainer. They will also be trained on how to use the study continuous glucose monitor (CGM) system, blood glucose meter, and ketone meter. Participants will have four mid-period follow up phone calls to review medications, ongoing eligibility, and solicit any occurrences of adverse events and device issues. At the end of 13-weeks, they will complete final visit tasks and will be transitioned back to their pre-study insulin delivery method with guidance provided by a study investigator.
  • Other: Routine Care — Participants will continue with their current diabetes treatment. Participants will be trained on the use of the study blood glucose meter. They will have four mid-period follow up phone calls to review medications, ongoing eligibility, and solicit any occurrences of adverse events. At the end of 13-weeks, they will complete final visit tasks and will be asked if they would like to participate in the observational extension phase where they will use the iLet Bionic Pancreas for 13 weeks.
Study Locations (2 sites)
University of Colorado Anschutz Medical Campus, Aurora, Colorado 80045 United States
Massachusetts General Hospital, Boston, Massachusetts 02114 United States
Eligibility Criteria
Inclusion Criteria: 1. Age at time of consent \>18 and \<89 years 2. Either 2.a. or 2.b.: 1. Clinical diagnosis of type 1 diabetes for at least one year and using insulin for at least 1 year 2. Clinical diagnosis of type 2 diabetes, on current injected or infused insulin regimen for at least 3 months prior to screening (e.g., basal-bolus, basal only, or pre-mix) 3. Stable doses of glucose lowering medications over the preceding 4 weeks as determined by Investigator, including GLP-1 receptor agonists (GLP-1 RA) and GLP-1/GIP RA agents 4. Stable doses of weight loss medications (including GLP-1 RA and GLP-1/GIP RA agents) over the preceding 4 weeks as determined by the investigator. 5. For those using the iLet Bionic Pancreas (during the RCT arm or observational extension phase), willingness to stay on current doses of medications throughout the study that may affect glycemia directly and/or indirectly, except for a dose reduction or discontinuation. 6. Have a primary care clinician willing to refer them to the study, confirm their diabetes diagnosis (for example: type 1 diabetes or type 2 diabetes), and recommend and manage the iLet for the duration of the study 7. Willing to comply with all study procedures for the duration of the study 8. Willing to wear a Dexcom CGM device and iLet system for duration of time randomized to iLet use or OEP 9. Willing to use the following insulin: lispro (including non-branded lispro and Humalog) or aspart (including non-branded aspart, Fiasp, and Novolog) 10. Investigator has confidence that the participant has the cognitive ability and can successfully operate all study devices and can adhere to the protocol 11. Willing and able to sign and date the Informed Consent Form (ICF) 12. If capable of becoming pregnant, willing and able to have pregnancy testing and use an acceptable method of contraception during the study period a. Capable of becoming pregnant means that menstruation has started and the participant is not surgically sterile or post-menopausal (12 months without menses) b. Acceptable methods of contraception include: i. Combined estrogen and progestogen containing hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal). ii. Progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable). iii. Placement of an intrauterine device or intrauterine hormone-releasing system. iv. Barrier methods of contraception (condom or occlusive cap with spermicidal foam/gel/film/cream/suppository). v. Has a vasectomized or sterile partner (where partner is sole partner of participant) and where vasectomy has been confirmed by medical assessment. vi. Exercises true sexual abstinence. Sexual abstinence is defined as refraining from heterosexual intercourse during the entire period of risk associated with the study. 13. Agreement to adhere to Lifestyle Considerations (see Section 5.3) throughout study duration 14. Have hardware and internet access capable of 2-way video and audio communication Exclusion Criteria: 1. Unable to safely comply with study procedures and reporting requirements (e.g. impairment of vision or dexterity that prevents safe operation of the bionic pancreas, impaired memory) 2. Unable to speak and read English, as iLet BP support materials and device menus are currently available in English only 3. Diagnosis of maturity-onset diabetes of the young (MODY) 4. Plan to change usual diabetes regimen between screening and study randomization 1. This would include changing from MDI to pump or from pump to MDI, starting a new class of type 2 diabetes medication, or starting or increasing GLP-1 RA or GLP-1/GIP RA medication 2. This would NOT include changes to any insulin doses, including pump settings, short- and/or long-acting insulin doses and type of insulin; changing type 2 diabetes medication dosing (except GLP-1 RA or GLP-1/GIP RA); or changing type of type 2 diabetes medication within the same class 5. Weigh more than 255 kg (561 pounds) as this is the maximum weight that can be entered into the iLet user interface 6. History of bariatric surgery within 12 months prior to enrollment or plans for bariatric surgery within the period of study participation 7. Current use of a closed-loop or hybrid closed-loop insulin delivery system that is not FDA-cleared (e.g. "DIY Loop", "AAPS", "iAPS" or "Open APS") 8. Diagnosed blood disorder or dyscrasia associated with hemolysis, including for example: sickle cell disease and thalassemia, which in the Investigator's opinion could interfere with HbA1c accuracy 9. Planned use of hydroxyurea at any dose and/or of acetaminophen at doses exceeding 1 gram (1000 mg) every 6 hours. 10. Plans to receive a blood transfusion over the course of the study or has received a transfusion within 3 months prior to enrollment 11. Current participation in another diabetes-related clinical trial 12. History of diabetes due to cystic fibrosis, pancreatitis, or other pancreatic disease, including pancreatic tumor or insulinoma, or history of complete pancreatectomy 13. Have a history of intermittent oral or injectable glucocorticoid treatment within 8 weeks prior to screening or plans to take intermittent oral or injectable glucocorticoid during the study (chronic, stable treatment is acceptable, unplanned use is acceptable) 14. History of more than 1 episode of diabetic ketoacidosis (DKA) or hyperglycemic hyperosmolar syndrome (HHS) in the 6 months prior to screening, unrelated to an intercurrent illness or to a kinked, dislodged, or occluded cannula 15. Established history of allergy or severe reaction to adhesive or tape that must be used in the study 16. Treated currently or within the past 30 days prior to enrollment, or plan to begin treatment, with sulfonylurea, pramlintide, or SGLT-2 inhibitor medication 17. Any planned surgery during the study that would be considered major in the opinion of the investigator 18. Pregnant or lactating, or planning to become pregnant in the next 6 months 19. Renal failure on dialysis or chronic renal disease with a GFR or eGFR \<30mL/min (values within the last two years will be accepted; if none available or \>2 years prior, participant will be instructed to obtain GFR or eGFR through their usual care provider and to make copy of result available to study team) 20. Any condition or circumstance that, in the opinion of the site principal investigator, could interfere with the safe or effective completion of the study or which could compromise the results of the study c. Conditions to be considered by the investigator may include, but are not limited to, the following: i. Active clinical diagnosis of substance use disorder ii. Chronic use of opiates and/or benzodiazepines which, in the opinion of the investigator, might make it difficult for the participant to follow study procedures iii. Coronary artery disease that is not stable with medical management, including unstable angina, angina that prevents moderate exercise (e.g. exercise of intensity up to 6 METS) despite medical management, or within the last 12 months before screening, a history of myocardial infarction, percutaneous coronary intervention, enzymatic lysis of a presumed coronary occlusion, or coronary artery bypass grafting iv. Known history of prolonged QTc interval, malignant arrhythmia, or severe congenital heart disease v. Congestive heart failure with New York Heart Association (NYHA) Functional Classification III or IV vi. History of TIA or stroke in the last 12 months vii. Untreated or inadequately treated mental illness viii. History of untreated or inadequately treated eating disorder within the last 2 years, such as anorexia, bulimia, or diabulimia, or omission of insulin to manipulate weight ix. History of intentional, inappropriate administration of insulin leading to severe hypoglycemia requiring treatment 21. Plans to travel outside of th
Conditions Non-Alcoholic Fatty Liver Disease, Type ...
Phase PHASE4
Enrollment 60
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

In this study the investigators will quantitate hepatic mitochondrial fluxes in T2D patients with NAFL and NASH before and after 16-weeks treatment with the insulin sensitizer pioglitazone

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: Single

Interventions / Regimen

  • Drug: Pioglitazone — An insulin sensitizer and anti-diabetic agent. Participants will be started on 15 mg/day, increased to 30 mg/day at week 2 and then to 45 mg/day at week 4.
  • Other: Placebo — Placebo for pioglitazone

Primary Outcomes

  • Effect of pioglitazone on hepatic mitochondrial TCA cycle fluxes (Baseline, week 16)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2022-11-01
Completion: 2027-03-31
Eligibility
Age: 18 Years – 80 Years
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The University of Texas Health Science Center at San Antonio
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Principal Investigators:
  • Luke Norton, PhD (PRINCIPAL_INVESTIGATOR) - The University of Texas Health Science Center at San Antonio
Contact Information
Study Contact:
Luke Norton, PhD
210-567-0739
nortonl@uthscsa.edu
Andrea Hansis-Diarte, MPH
210-567-3208
hansisdiarte@uthscs.edu
Andrea Hansis-Diarte, MPh
210-567-6691
hansisdiarte@uthscsa.edu
Texas Diabetes Institute - University Health System
Interventions
  • Drug: Pioglitazone — An insulin sensitizer and anti-diabetic agent. Participants will be started on 15 mg/day, increased to 30 mg/day at week 2 and then to 45 mg/day at week 4.
  • Other: Placebo — Placebo for pioglitazone
Study Locations (2 sites)
Texas Diabetes Institute - University Health System, San Antonio, Texas 78207 United States
University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229 United States
Eligibility Criteria
T2D with NAFL Inclusion Criteria: * Confirmed T2D based on OGTT (2 h glucose ≥200 mg/dl). * Treated with diet, metformin, and/or sulfonylurea and in good general health determined by medical history, physical exam, and routine blood chemistries; * age = 18-80 years; * BMI = 25-40 kg/m2; * HbA1c = 7-10%; stable body weight (±4 pounds) over the preceding 3-months; * not taking any medication known to affect glucose metabolism other than antidiabetic medications. * Evidence of moderate/severe fatty liver (steatosis; grade S2/S3 on FibroScan corresponding to ≥10% fat on MRI-PDFF) and no/minimal hepatic fibrosis (grade F0/F1 on FibroScan). Exclusion Criteria: * Alcohol consumption \>14 units/week for women and \>21 units/week for men. * Liver cirrhosis (fibrosis stage 4). * Evidence of other forms of chronic liver disease, including alcoholic liver disease, hepatitis B and C, primary biliary cholangitis, suspected/proven liver cancer and any other liver disease other than NAFLD. * Type 1 diabetes and/or GAD positive subjects. * Subjects not drug naive or have been on metformin more than 3 months. * Presence of proliferative retinopathy. * Urine albumin excretion \> 300 mg/day. * History of NY Class III-IV heart failure T2D with NASH Inclusion Criteria: * Confirmed T2D based on OGTT (2 h glucose ≥200 mg/dl). * Treated with diet, metformin, and/or sulfonylurea and in good general health determined by medical history, physical exam, and routine blood chemistries; * age = 18-80 years; * BMI = 25-40 kg/m2; * HbA1c = 7-10%; * stable body weight (±4 pounds) over the preceding 3-months; * not taking any medication known to affect glucose metabolism other than antidiabetic medications. * Evidence of moderate/severe fatty liver (steatosis; grade S2/S3 on FibroScan corresponding to ≥10% liver fat on MRI-PDFF) and moderate/severe hepatic fibrosis (grade F2/F3 on FibroScan). Exclusion Criteria: * Alcohol consumption \>14 units/week for women and \>21 units/week for men. * Liver cirrhosis (fibrosis stage 4). * Evidence of other forms of chronic liver disease, including alcoholic liver disease, hepatitis B and C, primary biliary cholangitis, suspected/proven liver cancer and any other liver disease other than NAFLD. * Type 1 diabetes and/or GAD positive subjects. * Subjects not drug naive or have been on metformin more than 3 months. * Presence of proliferative retinopathy. * Urine albumin excretion \> 300 mg/day. * History of NY Class III-IV heart failure